Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12;13(12):2525-2531.
doi: 10.1158/2159-8290.CD-23-1194.

Precision Oncology: 2023 in Review

Yonina R Murciano-Goroff  1 , Sarah P Suehnholz  2   3 , Alexander Drilon  1   4 , Debyani Chakravarty  2   3
Affiliations
Review

Precision Oncology: 2023 in Review

Yonina R Murciano-Goroff et al. Cancer Discov. .

Abstract

This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.

PubMed Disclaimer

References

    1. Rosen E, Drilon A, Chakravarty D. Precision oncology: 2022 in review. Cancer Discov 2022;12:2747–53. - PubMed
    1. Sacher A, LoRusso P, Patel MR, Miller WH, Garralda E, Forster MD, et al. . Single-agent Divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med 2023;389:710–21. - PubMed
    1. Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, et al. . Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv 2023;9:eade3816. - PMC - PubMed
    1. Murciano-Goroff YR, Heist RS, Kuboki Y, Koyama T, Ammakkanavar NR, Hollebecque A, et al. . A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14–19; Orlando, FL. Philadelphia (PA): AACR; 2023. Abstract nr CT028.
    1. Koltun ES, Rice MA, Gustafson WC, Wilds D, Jiang J, Lee BJ, et al. . Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8–13. Philadelphia (PA): AACR; 2022. Abstract nr 3597.

Publication types

Substances